By Drug Target Review2025-10-09T09:17:24
UCLA researchers have developed a monoclonal antibody, AD-NP1, that blocks ENPP1 to enhance heart repair and reduce scar tissue.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2024-05-10T11:23:31
Sponsored by BellBrook Labs
2023-01-05T14:41:33
Sponsored by Cell Signaling Technology
2023-01-04T16:08:55
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2023-03-03T14:06:14
Sponsored by Bio-Techne
2023-07-04T10:05:58
Sponsored by Revvity
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud